Arecor Therapeutics (AREC), a globally focused biopharmaceutical company, has shared positive results from its second Phase I clinical trial on its ultra-rapid-acting insulin candidate, AT247. Results from the trial showed that AT247 demonstrated faster absorption compared to standard insulins, meeting an urgent need for a more rapid-acting insulin analogues.
The results were presented in a poster session at the American Diabetes Association 83rd Scientific Sessions meeting.
The company had previously announced headline results from the trial on October 11, 2022.
AT247 is a novel formulation of insulin with a concentration of 100 units/mL. It has been specifically designed to enhance the absorption of insulin after injection, providing improved management of blood glucose levels for individuals with diabetes. During the Phase I trial, AT247 demonstrated faster absorption compared to standard insulins NovoLog® and Fiasp®.
Sarah Howell, Chief Executive Officer of Arecor, added: "These data reinforce AT247's potential to enable even more effective disease management for people with Type I diabetes. The availability of a truly ultra-rapid acting insulin will be a key component in the move towards a fully closed loop artificial pancreas system, a potentially life changing treatment option for people living with diabetes, improving health outcomes and reducing the significant burden of managing this chronic disease. With AT247, Arecor has the ability to significantly advance the diabetic treatment landscape and, ultimately, deliver better health outcomes for patients."
View from Vox
Diabetes has become a pervasive global health issue, impacting approximately 10% of the adult population worldwide. With around 537 million adults currently living with diabetes, and the number expected to rise to 643 million by 2030 and 783 million by 2045, the burden on healthcare systems across the globe is immense and growing. Around 56 million individuals rely on daily insulin, a $22 billion global market.
As diabetes care progresses towards improved monitoring and tighter glucose control, there is a growing demand for faster-acting insulins. Within its clinical development programmes, its insulin-based candidate AT247 sits ahead of the curve by offering accelerated insulin absorption compared with currently available gold standard rapid acting insulins, making it a potential game changer once it comes to market.
Arecor Therapeutics’ other insulin analogue, AT278, is also progressing well through trials, meeting all of its primary and secondary endpoints in its Phase I clinical trial completed in April last year.
Looking forward, Arecor will continue to build on its Arestat technology platform, which underpins the development of its diabetes medicines, with 2023 set to be a year of accelerated delivery across key areas of the business.
Follow Arecor Therapeutics for more News and Updates: